Want to see NKTR full AI Analyst Report?
NKTR Stock Chart & Stats
$84.86
-$0.04(-3.36%)
At close: 4:00 PM EST
$84.86
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$21.02 - $109.00
Previous CloseN/A
Volume706.47K
Average Volume (3M)1.20M
Market Cap
$2.46B
Enterprise Value$1.20B
Total Cash (Recent Filing)$568.60M
Total Debt (Recent Filing)$143.43M
Price to Earnings (P/E)―
Beta3.61
Next Earnings
Aug 06, 2026EPS Estimate
-2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.42
Shares Outstanding33,786,034
10 Day Avg. Volume1,640,135
30 Day Avg. Volume1,197,233
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue21.61
Enterprise Value/Gross Profit21.74
Enterprise Value/Ebitda-9.54
Forecast
1Y Price Target
$154.33Price Target Upside81.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-9.06
Revenue Forecast (FY)$41.22M
Bulls Say, Bears Say
Bulls Say
Durable Phase IIb EfficacyDurable, deepening responses in Phase IIb AD and AA materially de‑risk later stages: sustained EASI and SALT gains imply a robust biological signal likely to hold in larger populations, improving chances of positive pivotal readouts, label strength, and long-term physician and patient adoption across chronic indications.
Pro‑forma Cash RunwayA >$1B pro‑forma balance gives the company durable financing to execute multi‑site Phase III programs and manufacturing scale‑up without immediate refinancing pressure; this reduces near‑term dilution risk, strengthens negotiating leverage with partners, and supports sustained clinical development through key milestones.
Differentiated MOA And SafetyA differentiated Treg‑based mechanism with a favorable safety profile versus JAKs confers a durable competitive edge for chronic indications: fewer monitoring constraints and better tolerability can broaden prescribing, support long‑term adherence, and position the drug as a preferred systemic option, aiding market penetration.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow (~‑$204M TTM) means the business must rely on financing or existing reserves to fund pivotal trials and operations; persistent burn elevates dilution risk, constrains capacity for parallel programs, and keeps the company sensitive to capital markets over the medium term.
Large Operating Losses And Rising R&DRamp in R&D spending to support multiple Phase III programs will widen operating losses before potential revenue generation; without marketed products, the company must fund negative margins through cash or financing, increasing financial strain and placing high dependency on successful trial outcomes to justify continued investment.
Regulatory And Execution RiskOpen regulatory questions for alopecia areata and the operational complexity of large, multi‑region Phase IIIs raise execution risk: potential design changes, extra trials, or slow enrollment could delay approval, increase costs, and compress runway, making clinical timelines and commercial launch assumptions uncertain.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $21.02 and its highest was $109.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.46B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on May 07, 2026. The company reported -$1.82 earnings per share for the quarter, missing the consensus estimate of -$1.582 by -$0.238.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.04.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 33,786,034 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.82 in its last earnings report, missing expectations of -$1.582. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.33 (81.87% Upside)
$154.33 (81.87% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 377.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.15%
12-Months-Change
Fundamentals
Return on Equity
-87.00%
Trailing 12-Months
Asset Growth
197.87%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered strong clinical progress and a clear, accelerated path to Phase III for REZPEG in atopic dermatitis and alopecia areata, supported by robust Phase IIb data (durable and deepening responses, EASI‑100 increases, SALT‑20 gains) and a fortified balance sheet (> $1B pro forma). Key positives include well‑defined Phase III designs, meaningful market opportunity, favorable safety signals versus JAK inhibitors, and additional pipeline and TrialNet collaboration in type 1 diabetes. Main concerns are typical biotech risks: ongoing net losses and increasing R&D spend as Phase III programs start, noncash interest expense, remaining regulatory/endpoint design questions (especially for AA and potential moderate AA expansion), and operational enrollment/execution risk for global trials. On balance, the positives (clinical validation, financing, program advancement) outweigh the near‑term financial and execution risks.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$154.33
▲(81.87% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
2.98% Insiders
13.81% Mutual Funds
0.06% Other Institutional Investors
71.15% Public Companies and
Individual Investors